Repligen Co. (NASDAQ:RGEN) Shares Purchased by Zions Bancorporation N.A.

Zions Bancorporation N.A. grew its holdings in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 48.9% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 14,079 shares of the biotechnology company's stock after purchasing an additional 4,626 shares during the quarter. Zions Bancorporation N.A.'s holdings in Repligen were worth $2,027,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the business. Vanguard Group Inc. raised its position in Repligen by 1.1% in the fourth quarter. Vanguard Group Inc. now owns 5,101,090 shares of the biotechnology company's stock worth $734,251,000 after acquiring an additional 56,723 shares during the period. Conestoga Capital Advisors LLC raised its holdings in Repligen by 0.7% in the 4th quarter. Conestoga Capital Advisors LLC now owns 947,582 shares of the biotechnology company's stock worth $136,395,000 after purchasing an additional 6,872 shares during the period. DF Dent & Co. Inc. lifted its position in Repligen by 31.0% during the third quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company's stock valued at $87,852,000 after purchasing an additional 139,615 shares in the last quarter. New York State Common Retirement Fund increased its position in Repligen by 2.5% in the fourth quarter. New York State Common Retirement Fund now owns 581,442 shares of the biotechnology company's stock worth $83,693,000 after buying an additional 14,398 shares in the last quarter. Finally, Stephens Investment Management Group LLC lifted its position in shares of Repligen by 7.4% during the 4th quarter. Stephens Investment Management Group LLC now owns 536,801 shares of the biotechnology company's stock valued at $77,267,000 after buying an additional 37,057 shares in the last quarter. Institutional investors own 97.64% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on RGEN shares. StockNews.com cut shares of Repligen from a "hold" rating to a "sell" rating in a research note on Friday, February 21st. Evercore ISI began coverage on Repligen in a report on Tuesday, March 18th. They set an "in-line" rating and a $155.00 price target on the stock. Royal Bank of Canada boosted their price objective on Repligen from $203.00 to $205.00 and gave the company an "outperform" rating in a research report on Friday, February 21st. Canaccord Genuity Group assumed coverage on Repligen in a research report on Tuesday, December 17th. They set a "hold" rating and a $165.00 target price for the company. Finally, HC Wainwright reissued a "buy" rating and issued a $180.00 price target on shares of Repligen in a report on Friday, February 21st. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and eight have given a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $178.64.

Insider Transactions at Repligen

In related news, Director Margaret Pax acquired 250 shares of the firm's stock in a transaction that occurred on Monday, March 17th. The stock was purchased at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the purchase, the director now directly owns 1,043 shares of the company's stock, valued at $157,169.67. This trade represents a 31.53 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 1.20% of the company's stock.

Repligen Trading Down 2.7 %

RGEN traded down $3.71 on Friday, reaching $133.41. 856,653 shares of the company traded hands, compared to its average volume of 673,469. The company has a market cap of $7.49 billion, a P/E ratio of -261.59, a price-to-earnings-growth ratio of 4.54 and a beta of 0.95. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. Repligen Co. has a one year low of $113.50 and a one year high of $184.98. The firm has a fifty day simple moving average of $154.21 and a two-hundred day simple moving average of $148.15.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, beating the consensus estimate of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The firm had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. As a group, equities research analysts expect that Repligen Co. will post 1.72 earnings per share for the current year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.